Letter: Formalin-fixed tumour cells in the leukocyte migration test.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C E Ross.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The challenges of integrating behavioral healthcare delivery and the demand for better management of behavioral healthcare benefits require corporate risk managers to focus on issues of quality and outcomes. A strategic partnership between the employer and a managed care organization is one tool for reducing risk and improving the quality of services for beneficiaries, using the techniques of total quality management. The following article describes a six-step process for launching such a strategic partnership, along with some potential pitfalls.
We employed immunological tests to assess patients with cancer, mainly melanoma, receiving BCG alone or combined with chemotherapy. A comparison of BCG recipients with similar cancer patients not receiving BCG showed differences in the frequency of Mantoux reactivity positivity in the leucocyte migration assay against tumour antigens and positivity in membrane immunofluorescence. Short term sequential studies showed conversion from negativity to positivity or strengthening of reaction to occur during initiation of BCG therapy. Extended sequential studies employing the leucocyte migration assay against tumour antigens and modifications to assess serum effects indicate that the changes are more related to the changing clinical status than to BCG. It may be possible to devise quantitative in vitro techniques to assay sensitivity to tuberculoproteins which may allow assessment of BCG effects in vitro. Current technology permits monitoring for varying clinical stage rather than the effects of immunotherapy.